The Department of Justice announced on April 12th that Danco Laboratories, LLC reached a settlement to resolve alleged violations of the False Claims Act. According to the government, from a period of 2011 through 2019 “Danco failed to mark imported pharmaceutical products with the appropriate country of origin, and thereafter violated the False Claims Act by knowingly avoiding the marking duties owed to the United States for those imports.” Danco distributes a single pharmaceutical product, the abortifacient pill Mifeprex (a brand name of mifepristone).
The pharmaceutical distributing company based in New York City agreed to pay the U.S. Government $765,000. Companies that import foreign products are required by the Tariff Act of 1930 to mark the origin of the products.
Principal Deputy Assistant Attorney General Brian M. Boynton, head of the Justice Department’s Civil Division said that “this settlement demonstrates the department’s commitment to ensure that importers properly pay all amounts due under our customs laws.”
The claims against Danco originated from a whistleblower, the Life Legal Defense Foundation. The legal non-profit, which describes itself as a “pro-life, pro bono law firm,” filed through the qui tam provisions of the False Claims Act.
Qui tam claims enable private citizens to file lawsuits on behalf of the government if they know of an individual or company defrauding the government. Qui tam whistleblowers are eligible to receive between 15 and 30% of...
“Hey #Southafrica, Musk didn't have the decency to shake your president's hand. Musk helped get Malema sentenced. Don't believe for a second he won't target Ramaphosa,” reads the X post published ...